The company has small molecule product development programs for cancer, anxiety, epilepsy, and multiple sclerosis, with its lead cancer compound, BNC 105, being developed to shut down the blood supply within a tumor. Bionomics Limited has commercial partnerships with several companies and generates all of its revenues from Australia. The company's Drug Discovery and Development segment is engaged in the discovery, development, and commercialization of compounds to match a target product profile. Bionomics is a clinical-stage biopharmaceutical that is advancing its lead product candidate, BNC210, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder, and has a strategic partnership with Merck & Co., Inc. for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.